Kihara James 4

What Happened
Kihara James, ACADIA Pharmaceuticals’ Principal Accounting Officer, sold 1,030 shares in an open-market transaction on April 7, 2026, at a weighted average price of $22.20 per share for proceeds of $22,866. The Form 4 also reports a conversion/exercise event on April 5, 2026 for 2,010 restricted stock units (RSUs) that vested and converted into common shares; a portion of those shares were immediately disposed/withheld to cover taxes.

Key Details

• Transaction dates: RSU conversion/exercise on 2026-04-05; open-market sale on 2026-04-07.
• Sale: 1,030 shares sold at a weighted average price of $22.20; total proceeds $22,866. (Sales executed at prices ranging $22.07–$22.20.)
• Derivative/vesting: 2,010 RSUs converted/settled on 2026-04-05; a reported disposition of 2,010 shares at $0.00 reflects shares withheld/surrendered for tax withholding.
• Footnotes: RSUs represent a contingent right to one share each (F1); mandatory sales were to cover withholding/tax items and intended to comply with Rule 10b5‑1(c) (F2); RSUs vest in four equal annual installments beginning April 5, 2023 (F4).
• Shares owned after the transactions: Not disclosed in the Form 4.
• Filing timeliness: Report filed 2026-04-07 for transactions on 2026-04-05—filed within the usual Form 4 reporting window (timely).

Context
This filing shows RSU vesting and associated tax-related transactions rather than an independent, discretionary investment decision. The exercise/conversion of RSUs and the subsequent sale/withholding to satisfy taxes is common executive compensation administration and is often reported as a conversion (derivative) plus a sale or surrender of shares.